Explore cutting-edge oesophageal cancer research with Novotech CRO's disease report. Learn about new treatments, clinical trials, and future innovations in oesophageal cancer care.
Oesophageal cancer is the 11th most diagnosed cancer and the 7th leading cause of cancer mortality. It starts in the esophagus, the tube that moves food from the throat to the stomach. The two main types, oesophageal adenocarcinoma, and oesophageal squamous cell carcinoma, develop in different oesophageal regions and are driven by distinct genetic changes. Symptoms often remain unnoticed until the cancer spreads. Oesophageal cancer is more common in men than women, with global Age Standardized Incidence Rates (ASIR) of 7.6 and 2.6, respectively. The overall five-year survival rate is about 20%, varying from 5% to 50%. Early detection improves the survival rate. Oesophageal cancer cases are projected to increase significantly, potentially surpassing 923,000 new cases annually by 2050.
The NCCN, ESMO, and Japan Oesophageal Society provide guidelines for oesophageal cancer treatment. The NCCN (2024) recommends oxaliplatin for first-line therapy, with specific regimens for adenocarcinoma and squamous cell carcinoma based on biomarkers. ESMO suggests platinum-fluoropyrimidine chemotherapy with immune checkpoint inhibitors for advanced SCC, followed by nivolumab or pembrolizumab for second-line treatment. The Japan Oesophageal Society advises a combination of 5-FU, cisplatin, and nivolumab/pembrolizumab for first-line therapy, with subsequent options depending on prior treatments. These guidelines aim to tailor treatment strategies for optimal patient outcomes.
Moving on to prevalence, oesophageal cancer poses a significant health burden with nearly 511,000 new cases and 445,400 deaths reported in 2022, globally. Asia recorded the highest incidence, followed by Europe, North America, and rest of the world regions. The country-wise incidence rates showed variations, with China, South Africa, United Kingdom, India and Japan having the highest rates among others. These diverse trends reflect the complex epidemiological landscape of oesophageal cancer across the world.
Regarding clinical trials, since 2019, the biotech and biopharma industry initiated over 1,500 oesophageal cancer trials. Asia-Pacific led in the number of trials conducted, followed by North America and Europe, while the rest of the world contributed moderately. Mainland China was prominent in Asia-Pacific while the United States led in North America. Significant research efforts are also seen in Spain in the European region and Israel in the rest of the world. In terms of patient recruitment trends, Asia-Pacific showed shorter recruitment durations and faster patient recruitment rates.
Next, moving on to the marketed and drug pipeline trends, there are diverse products offered by companies like Advanz Pharma Corp. Ltd, BeiGene Ltd., InnoKeys Pte. Ltd., and Simcere Pharmaceutical Group Ltd., covering antibody, and small molecule. Multiple ongoing Phase III trials also demonstrate continued efforts in developing these and other innovative drug modalities such as the bispecific or multispecific antibody, and peptide vaccine therapies. These and other research and development initiatives reflect the companies comprehensive efforts to address oesophageal cancer treatment complexities and improve patient outcomes
In conclusion,oesophageal cancer remains a global health challenge, but recent treatment advances have improved patient outcomes compared to the previous years. Disparities in global prevalence rates and healthcare infrastructure highlight the need for tailored approaches and strong healthcare initiatives. The use of chemotherapy, targeted therapies, and immune checkpoint inhibitors in oesophageal cancer trials reflects efforts to address treatment complexities and improve patient outcomes. Precision medicine and kinase-targeting therapies, like TKIs and monoclonal antibodies, offer promise in overcoming drug resistance and recurrence in ESCC. Collaboration among researchers, healthcare providers, and pharmaceutical companies holds promise for further progress in oesophageal cancer management and care.
Novotech, a global clinical CRO, has partnered with numerous biotech companies and completed hundreds of oncology projects, including those in immuno-oncology and advanced therapies for indications such as oesophageal cancer. Novotech supports over 5,000 clinical projects across all phases and bioequivalence studies. Recognized for its contributions, Novotech has received the CRO Leadership Award 2023 and has been the Asia-Pacific CRO Company of the Year since 2006.
Discover more about the global clinical trial landscape for oesophageal cancer by downloading our comprehensive disease report.